In biologic-naive patients with CD, there were no differences in clinical remission or disease progression between those who received risankizumab vs ustekinumab.

Johnson & Johnson’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), including Crohn’s disease, ulcerative colitis, moderate to severe plaque ...